ArticleRegenerative therapy2025
Bioactive and degradable collagen-based three-dimensional scaffold encapsulated with adipose mesenchymal stem cells-derived exosomes improved diabetic wound healing.
Article in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Extracellular Matrix-Based and Extracellular Matrix-Bioinspired Scaffolds for Extracellular Vesicle Delivery in Dental Pulp Regeneration: A Narrative Review.Biotech (Basel (Switzerland)) · 2026Review
- Adipose-Derived Stem Cell Exosomes in Diabetic Wound Repair: Molecular Crosstalk, Bioengineering Strategies, and Translational Challenges.Stem cells international · 2026Review
- Adipose-derived stem cell exosomes: from functional mechanisms to clinical translation in diabetic foot ulcer management.Frontiers in endocrinology · 2026Review
- Synergistic integration of exosomes and natural compounds in 3D-printed bioscaffolds: Revolutionizing diabetic wound healing through multifunctional therapeutic platforms.Iranian journal of basic medical sciences · 2026Review
- Advanced small extracellular vesicles delivery systems forExtracellular vesicles and circulating nucleic acids · 2026Review
- Stem cell-derived exosomes in wound healing: mechanistic insights and delivery strategies.Regenerative medicine · 2025Review
- Bioengineered nanoparticles for targeted topical delivery in wound healing: advances and future outlook.Nanomedicine (London, England) · 2025Review
- Bioactive and biodegradable hydrogel based on the dermal matrix loaded with microspheres containing vascular endothelial growth factor (VEGF) and interleukin (IL)-10 accelerated the healing of diabetic wounds in rats.Regenerative therapy · 2025Article
- Extracellular vesicles in stem cell-based gonadal regeneration: mechanisms, therapeutic potential, and translational challenges.Frontiers in veterinary science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A diabetic wound is the most frequent form of chronic wound. Because diabetic wounds have multiple factors contributing to their development, the best treatments involve using a combination of approaches. Herein we assessed whether bioactive and degradable bioengineered micro-porous collagen-based three-dimensional scaffold (CTS) encapsulated with adipose mesenchymal stem cells (ASCs)-derived exosomes could accelerate the wound healing process in diabetic rats. Diabetic animals were assigned to the control group, CTS group, Exo group, and CTS+Exo group. Tissue samples were collected on days 7, 14, and 21 for evaluations including stereological, molecular, and tensiometrical assessments. The findings showed that in the treatment groups, there was a notably increase in wound closure rate, total volumes of newly formed epidermis and dermis, numerical densities of fibroblasts and blood vessels, collagen density, and biomechanical parameters than the control group, with the most noticeable changes seen in the CTS+Exo group. Additionally, there was a notably increase in the transcript of miRNA-146a, TGF-β, bFGF, and VEGF genes in the treatment groups than the control group, with the highest expression observed in the CTS+Exo group. In the CTS+Exo group, there was a much greater decrease in TNF-α and IL-1β expression, as well as in the number of neutrophils, compared to the other groups. These results validated that the combination of CTS and ASCs-derived exosomes has a greater effect on improving diabetic wound healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.